BioLargo, Inc. reported a consolidated revenue of $17.8 million for the fiscal year ending December 31, 2024, marking a 45% increase from the previous year’s revenue of $12.3 million. The growth was driven primarily by a 46% rise in product sales, particularly from the Pooph-branded pet odor control product, which accounted for 77% of total revenue. Despite this revenue increase, the company recorded a net loss of $4.35 million, a slight improvement from the $4.65 million loss reported in 2023. The loss per share remained consistent at $0.01 for both years.
The company’s operational segments showed varied performance. ONM Environmental, which focuses on odor and VOC control products, generated $15.6 million in revenue, a 36% increase from 2023, largely due to increased sales of the Pooph product. Conversely, BioLargo Engineering, Science & Technologies (BLEST) reported a significant revenue increase of 183% to $2.2 million, attributed to new engineering contracts. However, Clyra Medical, which is developing the Bioclynse surgical wound irrigation product, reported an operating loss of $3.3 million, with no revenue generated during the year.
Strategically, BioLargo has made significant advancements in its product offerings and organizational structure. The company has focused on expanding its water treatment technologies, particularly the Aqueous Electrostatic Concentrator (AEC) designed to remove PFAS contaminants. The AEC has been validated in pilot studies and is expected to meet new EPA regulations, potentially increasing demand for its water treatment solutions. Additionally, the company has strengthened its board with industry veterans to enhance its market presence in the water treatment sector.
Operationally, BioLargo has faced challenges, including a reliance on a single customer for a substantial portion of its revenue, which poses risks if that relationship falters. The company employed 44 individuals as of March 2025, with plans to expand its workforce to meet growing demand. The company’s cash position at year-end was $3.5 million, with ongoing concerns about its ability to sustain operations without additional financing. BioLargo anticipates continued net losses and cash flow challenges in the near future, emphasizing the need for strategic partnerships and effective marketing to drive product adoption and revenue growth.
Looking ahead, BioLargo remains focused on commercializing its innovative technologies while navigating the complexities of market acceptance and regulatory approvals. The company plans to leverage its existing partnerships and explore new opportunities to enhance its product offerings and expand its market reach. However, the ongoing need for capital raises concerns about its long-term viability, as it continues to rely on equity financing to support its operations and growth initiatives.
About BIOLARGO, INC.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.